<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Granulocytic phagocytosis ability (phagocytosis index in peripheral blood and in skin chamber exudate) and in vivo chemotaxis (skin chamber leukocyte mobilisation) were investigated in 22 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (19 men, three women, mean age 66.1 [46-82] years) </plain></SENT>
<SENT sid="1" pm="."><plain>The control group consisted of 20 young, healthy subjects (13 men, seven women, mean age 25 [22-27] years) </plain></SENT>
<SENT sid="2" pm="."><plain>The studies were repeated in twelve of the patients after 10 days of low-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> therapy (10 mg twice daily subcutaneously) </plain></SENT>
<SENT sid="3" pm="."><plain>Before treatment, total leukocyte mobilisation (TLM) after 24 hours (3.43 +/- 0.6 G/l.cm2) and phagocytosis index (PI(blood): 33.9 +/- 16.6%, PI(skin) chamber: 34.1 +/- 13.1%) were significantly lower (P &lt; 0.05) than in controls (TLM: 6.7 +/- 0.78 G/l.cm2, PI(blood): 59.6 +/- 17.8%, PI(skin) chamber: 37.4 +/- 18.1%) </plain></SENT>
<SENT sid="4" pm="."><plain>Following treatment for 10 days, the values were still depressed or had even worsened (TLM: 3.09 +/- 0.97 G/l.cm2; PI(blood): 35.6 +/- 24.1%, PI(skin) chamber: 19.9 +/- 8.6%; <z:hpo ids='HP_0000001'>all</z:hpo> P &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>Investigation of granulocytic function in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> may reveal evidence of reduced immune protection by these cells against <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Low-dose <z:chebi fb="0" ids="28680">cytarabine</z:chebi> therapy does not seem to affect cell differentiation </plain></SENT>
</text></document>